News
On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals ...
MyChesCo on MSN11h
Madrigal Pharmaceuticals Reports Promising Two-Year Data for Rezdiffra in MASH CirrhosisCONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced two-year results from the open-label arm of ...
Stocktwits on MSN22h
Madrigal Pharma Short Interest Reaches 4-Month High: Retail Investors Still Bullish On StockShort interest in Madrigal Pharmaceuticals rose to a four-month high, Ortex data showed, as bearish positions increased ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback